Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PDE1A | P54750 | 1/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559787 | 0.86 | MRGPRX4 (0.48) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL3547461 | 0.84 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4197597 | 0.81 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4199760 | 0.81 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4203741 | 0.78 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL2155319 | 0.77 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4352667 | 0.77 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL5006229 | 0.77 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL559949 | 0.77 | MTNR1A (0.47) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4203747 | 0.77 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344028-B2 | Gamma-amino-butyric acid derivatives as GABAB receptor ligands | XENOPORT, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2419401-A2 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS | XenoPort, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20120035139-A9 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2010120370-A2 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | PDE4A 1099/4885PDE4B 742/4885PDE4C 1743/4885 |
| US-20120035139-A9 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | PDE4A 1099/4885PDE4B 742/4885PDE4C 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.